IPG 8294
Alternative Names: IPG-8294Latest Information Update: 13 Feb 2024
At a glance
- Originator Immunophage Biotech
- Class Antidementias; Small molecules
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Mitochondrial myopathies
Most Recent Events
- 08 Feb 2024 Preclinical trials in Alzheimer's disease in China (unspecified route) before January 2024 (Immunophage Biotech Pipeline)
- 08 Feb 2024 Preclinical trials in Mitochondrial myopathies in China (unspecified route) before January 2024 (Immunophage Biotech Pipeline)
- 08 Feb 2024 Preclinical data released by Immunophage Biotech (Immunophage Biotech website, January 2024)